

August 6, 2024



Gelteq Strengthens Partnership with Monash Innovation Labs

Company benefits from robust ecosystem within the university, including premium facilities, talent, and expertise

MELBOURNE, Australia, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announces it is further strengthening its existing partnership with Australia's Monash University, which is [ranked #2 in the world in pharmaceutical science](#). The Company is establishing its new full-time research and development laboratory within the [Monash Innovation Labs](#), a key collaboration hub that provides access to advanced scientific and research facilities, technical expertise and STEM talent to growing Australian businesses.

Nathan Givoni, Gelteq's Co-Founder and Chief Executive Officer, stated, "Monash University is a premiere international research institution, and this partnership has allowed us to collaborate with top-tier researchers and innovators while also providing us access to talented students that contribute to our talent pipeline. Monash has already been an essential partner to Gelteq, providing access to dedicated state-of-the-art wet labs to conduct R&D. We are pleased to strengthen our existing partnership and continue to grow our company on a global scale with the support offered through this collaboration."

Being located at Monash Innovation Labs, Gelteq will be able to streamline its manufacturing capabilities and will also have access to Monash's top-of-the-line analytical testing labs, enhancing capabilities to take a product from an idea through to production, with the added ability to ensure that all regulatory requirements are addressed.

Professor Adrian Neild, Director of the Monash Innovation Labs and Deputy Dean (Strategic Initiatives) in the Faculty of Engineering at Monash University, stated, "We are pleased to partner with Gelteq and welcome the company into the Monash Innovation Labs community. Gelteq are at the forefront of medical delivery technology and we look forward to seeing the outcomes of their groundbreaking research and the mutual benefits of partnering with our STEM student talent."

About Gelteq

Headquartered in Melbourne, Australia, Gelteq is a global biotechnology company that specializes in the formulation, development, and manufacturing of an innovative ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq's unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.

Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements," including with respect to the proposed initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. All statements other than statements of historical facts are forward-looking statements. You can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include forward-looking statements include, but are not limited to, the risks and uncertainties described in "Cautionary Note Concerning Forward-Looking Statements;" "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the documents that referred to in the prospectus with the understanding that the Company's future results may be materially different from and worse than what we expect. Other sections of the prospectus include additional factors which could adversely impact our business and financial performance. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for the Company's management to predict all risk factors and uncertainties, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company and the underwriters qualify all of the forward-looking statements by these cautionary statements.

The prospectus contains certain data and information obtained from various government and private publications. Statistical data in these publications also include projections based on a number of assumptions. The robotics industry may not grow at the rate projected by market data, or at all. Failure of this market to grow at the projected rate may have a material and adverse effect on the Company's business and the market price of the shares of common stock. In addition, the rapidly evolving nature of this industry results in significant uncertainties for any projections or estimates relating to the growth prospects or future condition of the market. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based on these assumptions. You should not place undue reliance on these forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the prospectus relate only to events or information as of the date on which the statements are made in the prospectus. Neither the Company nor the underwriters undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read the prospectus and the documents that we refer to in the prospectus and have filed as exhibits to the registration statement, of which the prospectus is a part, completely and with the understanding that our actual future results may be

materially different from what we expect.

Media Contact:
CORE Public Relations
PR@gelteq.com



Source: Gelteq Pty Ltd